“Newly published research highlights key benefits of PectaSol-C in bladder cellular health.”
We don’t often hear about bladder cellular health, but it’s a critical area where many people are seeking active support. As the fourth most common cellular health topic among US men, and with the limitations of standard protocols, there’s an urgent need for researched solutions that effectively address bladder cellular health.
A new preclinical study on ecoNugenics PectaSol-C Modified Citrus Pectin provides some important answers. This new study highlights the benefits of PectaSol-C in bladder cellular health, via its actions against rogue protein, galectin-3 (Gal-3).
Published May 2018 in the medical journal, Acta Pharmaceutica Sinica, the new study examined the effects of PectaSol-C on two human bladder cell lines, and in a mouse xenograft model. Results showed that PectaSol-C significantly supported bladder cellular health, through inhibition of gal-3 and suppression of Akt signaling. Akt is protein kinase with roles in multiple cellular processes.*
These exciting findings are consistent with the large and fast-growing body of peer-reviewed data demonstrating the cellular health benefits of PectaSol-C in multiple cell types including prostate, breast, ovarian, colon and others.*
As the only proven gal-3 blocker and the only researched form of modified citrus pectin, PectaSol-C is earning an esteemed reputation for its broad-spectrum benefits and novel mechanisms of action. Because of its unique ability to block gal-3, PectaSol-C is increasingly studied in cellular health, cardiovascular health, liver and kidney function, and other key areas of health.
Results continue to demonstrate PectaSol-C to be a remarkable agent that offers unparalleled support for our most critical areas of health, safely and naturally.*
Source: Fang T, Liu DD, Ning HM, Dan Liu, Sun JY, Huang XJ, Dong Y, Geng MY, Yun SF, Yan J, Huang RM. Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3. Acta Pharmacol Sin. 2018 May 16. doi: 10.1038/s41401-018-0004-z.